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ABSTRACT: Heart disease is the leading cause of mortality and one of the main causes of 
morbidity  in  beta-thalassemia.  Patients  with  homozygous  thalassemia  may  have  either  a 
severe phenotype which is usually transfusion dependent or a milder form that is thalassemia 
intermedia. The two main factors that determine cardiac disease in homozygous β thalassemia 
are  the  high  output  state  that  results  from  chronic  tissue  hypoxia,  hypoxia-induced 
compensatory reactions and iron overload. The high output state playing a major role in 
thalassaemia  intermedia  and  the  iron  load  being  more  significant  in  the  major  form. 
Arrhythmias, vascular involvement that leads to an increased pulmonary vascular resistance 
and an increased systemic vascular stiffness and valvular abnormalities also contribute to the 
cardiac dysfunction in varying degrees according to the severity of the phenotype. Endocrine 
abnormalities, infections, renal function and medications can also play a role in the overall 
cardiac function. For thalassaemia major, regular and adequate blood transfusions and iron 
chelation  therapy  are  the  mainstays  of  management.  The  approach  to  thalassaemia 
intermedia, today, is aimed at monitoring for complications and initiating, timely, regular 
transfusions and/or iron chelation therapy. Once the patients are on transfusions, then they 
should  be  managed  in  the  same  way  as  the  thalassaemia  major  patients. If  cardiac 
manifestations of dysfunction are present in either form of thalassaemia, high pre transfusion 
Hb levels need to be maintained in order to reduce cardiac output and appropriate intensive 
chelation therapy needs to be instituted. In general recommendations on chelation, today, are 
usually made according to the Cardiac Magnetic Resonance findings, if available. With the 
advances in the latter technology and the ability to tailor chelation therapy according to the 
MRI findings as well as the availability of three iron chelators, together with increasing the 
transfusions as need, it is hoped that the incidence of cardiac dysfunction in these syndromes 
will be markedly reduced. This of course depends very much on the attention to detail with 
the monitoring and the cooperation of the patient with both the recommended investigations 
and the prescribed chelation. Medit J Hemat Infect Dis 2009; 1.
Introduction:  β-thalassemia  is  an  inherited 
hemoglobin  disorder  resulting  from  either 
homozygous or double heterozygous inheritance of 
two  abnormal  genes  from  the  β  – globin  locus, 
leading to impaired synthesis of the β-globin chain 
and resulting in chronic dyserythropoietic anemia.
1
Depending  on  the  clinical  severity,  two  forms, 
thalassemia  major  (ΤΜ)  and  thalassemia 
intermedia, (ΤΙ) are distinguished
1. The majority of 
patients have TM but up to 25% may have TI.
1 TM 
is  rapidly  fatal  unless  adequate  transfusions,  in 
conjunction  with  intensive  iron  chelation  therapy, 
are  started  sufficiently  early.
2 In  contrast,  TI  is 
generally characterized by a mild clinical picture, 
has  a  better  prognosis  and  survival  and  requires 
therapeutic interventions only later in life, if at all.
3 
The  clinical  course  of  both  forms  of  thalassemia 
(Th), if they remain untreated, is complicated by 
the multiple effects of chronic anaemia and of the 
resultant  tissue  hypoxia  as  well  as  by  their 
compensatory  reactions,  including  increased 
erythropoiesis  with  bone  marrow  expansion  and 
increased  intestinal  iron  absorption.
1 Those 
manifestations are completely or partially inhibited 
nowadays  in  TM  patients,  due  to  the  early 
application of regular transfusion-chelation therapy 
at the cost of chronic iron overload and the need for 
iron  chelation  therapy,  while  in  TI  patients  these 
features  are  still  present  in  varying  degrees. 
Cardiovascular  involvement  represents  a  well-
known complication and remains the primary cause 
of mortality both in TM and in TI.
2-4 As discussed 
below, it seems quite different in the two forms of 
the disease. Despite the fact that both forms share 
common  basic  underlying  pathophysiological 
mechanisms  that  affect  the  heart,  the  different 
degree of contribution of these mechanisms in TM 
and in TI, result in a variety of left and right heart 
involvement,  which  ultimately  lead  to  congestive 
heart failure. Knowledge of the complexity of the 
underlying mechanisms in thalassaemia may help to 
prevent or to treat the heart injury. 
Common  mechanisms of  heart  injury  in 
Thalassemia (Th): Cardiac structure and function 
in Th are mainly affected by two factors: iron load 
and increased cardiac output. Additional factors are 
involved and will be discussed. 
The cardiac iron load: Iron overload results from 
two  main mechanisms. In both TM  and TI, it  is 
associated with red  cell transfusion and increased 
intestinal iron absorption
1. The iron overload in TM 
is dominated by the transfusion iron, while in TI the 
absorption is the greatest source. Furthermore, the 
disease itself, including ineffective erythropoiesis as 
well  as  peripheral  haemolysis  results  in  selective 
tissue  iron  deposition.  Therefore,  although  iron 
overload is mainly a problem of TM patients, it also 
exists to a lesser extent in TI. The heart, along with 
liver  and  endocrine  glands,  is  one  of  the  main 
organs  where  iron  deposition  causes  severe 
complications.
5  Iron  overload  interferes  in  the 
cardiomyocytes’ capacity to catalyze the formation 
of  deleterious  oxygen  free  radicals.
5  The 
quantification  of  myocardial  iron  content  is  not 
generally easy and only T2* CMR has allowed a 
reliable  estimation  in  a  large  number  of  TM 
patients.
6 There are two mechanisms of iron related 
injury; these are direct and indirect. 
Direct Iron related injury: In TM survival was 
dependent  on regular  transfusion. Patients receive 
between  0.3-0.5  mg/Kg/day  of  iron  through 
transfusions. The average daily losses are less than 
1mg in males and 2 mgs in menstruating females. 
There  are  no  other  physiological  mechanisms  for 
effecting  body  iron  reduction;  therefore  the  body 
stores  the  iron. Before  the  availability  of  iron 
chelation  therapy,  the  majority  of  transfused  TM 
patients died, usually in the second and third decade 
of  life,  from cardiac  failure  that  was  due  to  iron 
overload.  In  TI  the  increased  gastro-intestinal 
absorption of iron, which is much higher than that 
in  normal  individuals  is  most  likely  due  to  a 
paradoxical  suppression  of  hepcidin.
7-9 In 
dyserythropoietic  anaemias,  this  suppression has 
recently been found to be induced by Matriptase-2, 
a  transmembrane  serine  protease.
10 Hepcidin 
interferes  in  iron  homeostasis  by  inhibiting  iron 
absorption from duodenal enterocytes, iron release 
from  hepatocytes  and  from  macrophages  that 
recycle iron from senescent erythrocytes.
7,8 In Th, 
the  accumulated  iron,  is  thought  to  saturate  liver 
firstly,  and  then  to  accumulate  in  other  organs. 
Therefore In the less loaded TI, the absorbed iron 
seems to  accumulate  mainly  in  the  liver and less 
frequently involves the heart. A number of studies 
using  CMR  T2*  have  demonstrated  this  finding.
One study in 31 TI patients revealed that 23% of 
cases had cardiac iron overload, defined as a T2* 
value <20 msec
11-13. The usual management of TI is 
clinical  observation  with  occasional  transfusions 
and intervention with regular transfusions and iron 
chelation  therapy  if  indicated.In  histological 
examination of the heart in patients with TM, the 
iron  accumulates  in  all  four  chambers,  papillary 
muscles  and  the  electrical  conduction  system, 
including the sinoatrial and atrioventricular nodes.
In the free wall of the left ventricle there is more 
iron concentrated in the epicardial layers than in the 
endocardial  and  middle  third
14.  Iron  is  stored  in Medit J Hemat Infect Dis 2009; 1.
cells,  including  myocytes,  in  the  form  of  ferritin, 
haemosiderin and free iron. The latter is referred as 
the  labile  cellular  iron  (LCI).
15 There  is a 
significant  flux  between  the  three  forms,  with 
haemosiderin being the least soluble and accessible. 
The LCI is the most toxic form as it stimulates the 
formation  of  free  radicals  (Fenton  Reactions), 
which results in peroxidative damage of membrane 
lipids  and  proteins  provoking  cellular  injury.  In 
heart,  this  leads  to  impaired  function  of  the 
mitochondrial  respiratory  chain  and  is  clinically 
manifested  by  reduction  of  cardiac  muscular 
contractility  and  CCF  development.
16 To  date,  at 
least  90  genes  that  control  iron  metabolism  have 
been identified.
17 In each individual therefore, it is 
highly likely that the handling of iron and the action 
of iron chelators will be different. These concepts 
fit in well with the wide range of reported different 
clinical cardiac courses seen mainly in TM patients 
who have followed similar life-time, well accepted 
treatment.
18 Knowledge  derived  by  recent  MRI 
studies  which  also  assessed  cardiac  function, 
showed that all patients with reduced LV function 
had cardiac iron overload and in  many cases this 
was  severe.
6,19,20 This  strongly  suggests  that  in 
addition to the damage caused by the accumulated 
iron,  excessive  iron  in  the  myocytes  results  in 
greater  amounts  of  LCI  leading  to  free  radical 
formation  that  overwhelms  the  antioxidant 
mechanisms  and  ultimately  precipitates  cardiac 
dysfunction. On the other hand, in the above MRI 
studies, despite heavy iron load, many TM patients 
maintained normal cardiac function, albeit perhaps 
temporarily, and, as discussed above, this may be 
related  to  their  intracellular  iron  metabolism,  in 
particular  their  handling  of  oxidants.  It  has  been 
shown  that  TM  individuals  who  had  the  genetic 
factor apo-lipoprotein E4 are at greater risk for LV 
dysfunction  than  those  with  other  alleles  such  as 
apo E2 and apo E 3 because of reduced ability to 
handle oxidative stress.
21,22
Indirect iron  related  injury: All  the  following 
factors related to indirect iron related cardiac injury 
are more common in TM than TI. However, they 
are relevant to both. 
Infections: Any significant infection may precipitate 
cardiac failure particularly in the presence of other 
underlying cardiac pathology. Immune competence 
in beta-thalassemia is impaired
23-26 and patients are 
more  vulnerable  to  infections.  Furthermore, 
siderophore  bacteria,  such  as yersinia  and 
klebsiella, rely on iron for multiplication and grow 
well  in  the  microenvironment  of  transfusion  iron 
loaded patients
25.Iron overload is considered to be 
the  main  etiologic  factor  that  can  disturb  the 
immune  balance  in  favour  of  the  growth  of 
infectious organisms.
24 This may also be affected 
by  differences  in  the  existing immunogenetic 
profile in  Th
26 especially  with  respect  to  viral 
infections. Two  severe  cardiac  complications, 
pericarditis and myocarditis, are linked to iron load 
induced  viral  infection  susceptibility.Pericarditis 
was  frequently seen  in  Th,   In TM  patients with 
poor  or  no  chelation  in  the  past
27  it  was  quite 
frequent  (50%). Today,  with  the  use  of  chelation 
therapy,  it  is  very  rare  (5%).
18 Similarly,  the 
reported  myocarditis  in  TM  with  decreased  LV 
function,
28 seems most likely to be related to iron 
load.  Even  though  there  may  be  histological 
evidence of  infections,  as  demonstrated  by 
lymphocytic  infiltration, recent  CMR  evidence 
shows that LV failure only occurs in the presence 
of  excessive  iron.
6,19,29 Viral  myocarditis  without 
iron in the heart may be rare and may follow similar 
outcomes to those of the normal population. 
Arrhythmias: The  iron induced cardiac toxicity is 
often  complicated  by  arrhythmias  such  as  extra 
atrial  and  ventricular  beats,  paroxysmal  atrial 
tachycardia, flutter or fibrillation. The high output 
state  may  also  be  related  to the  incidence  of 
arrhythmias  to  a  lesser  extent. Life  threatening 
ventricular tachycardia is rare and often associated 
with  reduced  LV  function.  Short  runs  of  non 
specific ventricular tachycardia are quite common 
and are more common with elevated cardiac iron
30.
Atrial arrhythmias occur more frequently in both TI 
and  TM. These  are  more  clinically  relevant  and 
difficult to treat. They do not necessarily relate to 
the degree of cardiac iron load at the time of onset, 
but may result from past damage caused by the iron 
load  or  high  cardiac  output. Some  of  these 
arrhythmias can also be triggering factors for CCF 
or reduced cardiac function in TM patients without 
previous obvious LV dysfunction.
Endocrine  abnormalities: Endocrine  abnormalities 
occur in Th but with greater frequency in TM. Iron 
toxicity may also indirectly affect heart function by 
damaging  other  organs  in  varying  degrees. The 
endocrine  abnormalities  hypothyroidism  and 
diabetes mellitus can have a significant impact on 
cardiac function.
31 Hypothyroidism can precipitate 
pericardial  effusion,  decreased  LV  function, 
bradycardia  and  increased  peripheral  vascular 
resistance. The onset of diabetes is often associated 
with the presentation of cardiac dysfunction. This 
correlates with a recent finding that pancreatic iron 
correlates  well  with  cardiac  iron  and  not  with 
hepatic  iron.
32 Chronic  hyperglycaemia  is  an 
oxidative  stress  on  many  organs,  particularly  the 
heart. Hypocalcaemia  associated  with  occult  or Medit J Hemat Infect Dis 2009; 1.
overt  hypoparathyroidism  can  precipitate  heart 
dysfunction.
Medications: Vitamin C has been given to patients 
with in order to enhance their iron excretion when 
they are on chelation therapy. There have been case 
reports of TM who developed sudden acute cardiac 
failure  with  a  fatal  outcome  that  had  been 
precipitated  by  the  administration  of  Vitamin  C 
possibly by releasing free iron that is toxic.
33
Vascular  Involvement  (After  load): Systemic 
arterial  involvement  in  Th,  has  been  observed 
recently  through  clinical,  functional
34 and 
anatomical
35 studies,  and  plays  a  role  in  the 
development  of  cardiac  dysfunction  by  affecting 
heart after load. Vascular involvement starts early 
in life and becomes obvious in the older patients,
36
principally  in  TI.  Haemolysis  participates  in  this 
injury as does iron overload, most likely through the 
effect  of  the  labile  plasma iron  (LPI). The  other 
contributory mechanisms will be discussed in detail 
below in the section on elastic tissue abnormalities. 
Increased  Cardiac  Output  (CO)  effect:  Disease 
related  increased  CO,  resulting  in  increased 
workload  on  the  heart,  contributes  to  the 
development of cardiac dysfunction in Th patients. 
Anemia together  with  marrow expansion  leads to 
volume  overload  that  then  demands  increased 
contractility.  (Starling’s  Law).In  normal 
individuals. Hb  levels  between  80-100 g/l  do  not 
have any effect on the resting cardiac output
37,38.
TM patients, however, even those well transfused 
(pre transfusion Hb level > 95 g/l) with excellent 
suppression of marrow activity and with a mean Hb 
level of 113 g/l, demonstrate some degree of high 
cardiac output (Cardiac Index 4.3±0.9/3.in TM cf. 
3.8±0.8 P<.01 in normal individuals).
18  In patients 
with high output state, the heart‘s systolic function 
index and ejection fraction is expected to be higher 
than in normal subjects. Thus, for Th patients, even 
well transfused TM, it has been recommended that a 
normal  LVEF  should  be  above  60%
39,40 and  the 
degree of CO increase should be taken into account 
when assessing EF in each individual patient
41. In 
those TM who are poorly transfused the increased 
cardiac output will be greater.  In TI, with minimal 
to  no  transfusion,  the  increased  cardiac  output 
represents  one  of  the  basic  pathophysiologic 
mechanisms of cardiovascular involvement and is a 
constant  finding.
42,43,44,45 More  specifically, 
echocardiographic  measurements  reveal an  almost 
two-fold increase in cardiac output levels, compared 
to  normal subjects (Table 1).
42 Indications of the 
presence of high output state were also derived by a 
cardiac magnetic resonance imaging (CMR) study 
in TI patients.
9 Chronic hemolytic anemia, resulting 
from ineffective erythropoiesis, is the hallmark of 
all thalassemia syndromes.
1 In TI, chronic anemia, 
however, is not always severe (hemoglobin levels 
range  usually  between  70  and  110  g/l)  and 
apparently is not the only cause of high output state 
in  these  patients.  Besides  the  overall  hemoglobin 
level, the proportions of the different hemoglobin 
types,  especially  the  high  percentage  of  fetal 
hemoglobin  (HbF),  are  also  important.  More 
specifically,  HbF  reduces  tissue  oxygen  delivery 
due  to  its  increased  oxygen  affinity.
46  Thus,  both 
chronic anemia and increased HbF percentage result 
in prolonged tissue hypoxia. This in turn, leads to a 
compensatory  bone  marrow  expansion,  with 
extramedullary  haemopoiesis,  splenomegaly  and 
hepatomegaly,  all  of which also  contribute to  the 
high output state through peripheral vasodilatation 
and shunt development.
42, 46-48 Similarly and more 
impressively, compensatory mechanisms also occur 
in  TM  who  are  not  adequately  transfused. In 
addition, vessels in Th are more susceptible to pulse 
pressure-driven  dilatation,  due  to  a  co-existent 
elastic tissue  injury, which is  discussed in  details 
below.  Liver  iron  load  or viral  induced  hepatic 
injury can also contribute, as cirrhosis can increase 
CO  significantly.
49 The  contribution  of  peripheral 
vasodilatation and intramedullary shunting seems to 
play  an  important  role  in  the  high  output  state. 
Indeed,  it  has  been  shown  that  the  abolition  of 
splenic  shunting  and  the  increase  in  hemoglobin 
level  following  splenectomy  are  not  sufficient  to 
counteract the preexistent high cardiac output levels 
in Th.
47, 48
Additonal Factors that impact on Cardiac Injury
Haemolysis-induced  tissue  injury  – Vascular 
involvement  and  elastic  tissue  abnormalities:
Chronic haemolysis and iron overload, are currently 
considered  as  sources  of  strong  oxidative  stress. 
Reports have shown that the free haeme and the red 
cell  membrane  elements that are  produced during 
haemolysis have a negative effect  on nitric oxide 
and  arginine  availability,  which  in  turn  promotes 
vasoconstriction.
50  At the same time,  they lead to 
further endothelial dysfunction, resulting in a more 
pronounced nitric oxide reduction, as well as to a 
diffuse elastic tissue injury. The presence of such an 
elastic tissue defect has been described with a high 
prevalence  in  patients  with  haemoglobinopathies, 
especially  in  those  with  Th.
36,51 The  defect 
resembles  hereditary  pseudoxanthoma  elasticum 
(PXE),  a  rare  (1:70000  to  1:160000)  connective 
tissue  disorder,  and  covers  the  whole  clinical 
spectrum  of  PXE,  which  consists  mainly  of  skin 
(small  yellowish  papules  or  larger  coalescent 
plaques), ocular and vascular manifestations 
Table 1. Data derived from a cohort previously published by Aessopos et al.
2Medit J Hemat Infect Dis 2009; 1.





Right ventricular diameter (mm) 234 193 <.001
Left atrial diameter (mm) 426 333 <.001
Left ventricular end-diastolic diameter (mm) 555 482 <.001
Left ventricular end-systolic diameter (mm) 324 272 <.001
Interventricular septum thickness (mm) 9.71.0 8.60.9 <.001
Posterior wall thickness (mm) 9.61.0 8.50.8 <.001
Left ventricular mass index (g/m
2) 12630 8610 <.001
Shortening fraction (%) 435 443 NS
Ejection fraction (%) 736 753 <.05
Cardiac index (l/min/m2) 5.451.33 3.820.80 <.001
Peak early transmitral diastolic velocity - E (cm/sec) 9920 8015 <.001
Peak late transmitral diastolic velocity – A (cm/sec) 6919 5812 <.001
E/A 1.510.48 1.420.34 NS
Ε deceleration time (msec) 15234 16433 NS
Isovolumic relaxation time (msec) 4715 5110 NS
Peak systolic tricuspid gradient (mmHg) 33.1514.06 20.774.23 <.001
Total pulmonary resistance (dynes∙sec∙cm
-5) 451294 24593 <.001
(degeneration  of  the  elastic  lamina  of  the  arterial 
wall,  often  with  calcification).
36,51 Endocardium, 
cardiac  valves  and  pericardium  may  also  be 
involved.
36,42 As  the  clinical  expression  of  the 
elastic tissue injury is  age-related,  TI patients are 
more  affected  by  PXE  lesions  due  to  their 
prolonged survival. Thus, it has been shown that TI 
patients  aged  >30  years  (mean  age  41.4  years) 
presented  a  55%  occurrence  of  tibial  artery 
calcification as part of elastic tissue abnormalities
52. 
Interestingly,  histopathological  studies  in  TI  have 
shown  it  to  be  present  in  removed  spleens  even 
from the first decade of life.
35 On the other hand, 
the  degenerative  arterial  lesions  observed  in  the 
elastic  lamina  and  adventitia  render  vessels  more 
susceptible to dilatation by pulse pressure increase. 
Finally,  the  functional  component  of  the  arterial 
involvement was recently studied in TM, sickle-cell 
anemia  and  sickle-thalassemia  patients.  Increased 
arterial stiffness along with endothelial dysfunction 
was encountered and attributed to the two common 
pathogenic  mechanisms,  namely  haemolysis  and 
iron load.
34,53
Valvular  involvement: Although  valvular 
involvement is present in Th, it is more pronounced 
in TI. Endocardial degenerative lesions, in the form 
of  thickening  and  calcification,  affect  the  cardiac 
valves,  mitral  annulus  and  papillary  muscles  and 
this  is  often  followed  by  moderate  valvular 
regurgitation  and  occasionally  by  aortic  stenosis.
These  findings  were  described 
echocardiographically  with  a  high  frequency  in  a 
large group of 110 TI patients.
42 More specifically, 
leaflet thickening was present in 48% of patients, 
endocardial  calcification  in  21%,  mitral 
regurgitation in 47%, aortic regurgitation in  15%, 
while  there  were  3  cases  with  mild  to  moderate 
aortic  stenosis.  The  hyperkinetic  state  due  to  the 
high  output,  the  iron  overload  and  primarily  the 
aforementioned  elastic  tissue  abnormalities  have 
been  suggested  as  the  responsible  pathogenic 
mechanisms.
42,43Although  the  haemodynamic 
consequences  of  the  above  mild  or  moderate 
valvular  abnormalities  are  not  usually  significant, 
they may have an additive effect when associated 
with  the  other  pathogenic  mechanisms  in  the 
development  of  heart  disease. Moreover, 
atrioventricular conduction disturbances as well as 
the risk of cerebrovascular thrombotic events, in the 
context of a coexistent hypercoagulable state, may 
also play a role.
42,54
Hypercoagulability: Is a well-described entity in 
Th.
55 A  number of  pathogenic  mechanisms  have 
been discussed in relation to the underlying genetic 
defect and its consequences, namely haemolysis and 
iron  overload  and  the  resulting  oxidative  tissue 
damage. More specifically, the free α-globin chains 
that result from the decreased synthesis of the β-
chains, along with the free iron provoke oxidative 
damage to  the  red  blood cell membrane  proteins; 
these changes result in the exposure of negatively 
charged  phospholipids,  which  create  a  pre-
coagulant surface.
55,56 Moreover, data derived from 
TM  and  sickling  syndromes,  as  described  above, 
showed  that  endothelial  function  is  also 
impaired.
34,53  Oxidative  damage,  resulting  once 
again  from  the  two  common  mechanisms, 
haemolysis  and  iron  load,  leads  to  an  increase 
expression  of  adhesion  molecules  ICAM  and 
VCAM  and  impaired  NO  bioavailability,  hence 
provoking  hypercoagulability  and  decreasing  NO-
dependent,  flow-mediated  dilatation.
34,57Medit J Hemat Infect Dis 2009; 1.
Furthermore, platelets are activated with enhanced 
aggregation,  while  splenectomy  increases  platelet 
counts  and  induces  membranes  abnormalities  that 
enhanced the already increased platelet aggregation. 
In  parallel,  the  observed  deficiency  of  the 
coagulation inhibitors, protein C and protein S, the 
elevated levels of thrombin-ATIII complex due to 
splenectomy and/or liver dysfunction as well as the 
co-inheritance of several coagulation defects, such 
as factor V (Leiden) and factor ΙΙ deficiency, may 
also  contribute  to  the  pathogenesis  of 
hypercoagulability  in  thalassemia.
55,58 Finally,  a 
strong  inflammatory  reaction  has  been  noticed, 
expressed  by  the  elevated  circulating  levels  of 
cytokines  and  adhesion  molecules,  and  the 




Vascular  manifestations:  The  combination  of 
hypercoagulability  and  haemolysis-related  elastic 
tissue abnormalities may lead to a wide spectrum of 
vascular  complications.  The  elastic  tissue 
abnormalities, on  one  hand, have been  associated 
with  a  number  of  vascular  complications,  which 
have  been  sporadically  observed  in  Th  patients. 
These findings include fatal cerebral haemorrhages, 
anginal  symptoms,  ascending  aorta  aneurysm 
formation and  gastrointestinal  bleeding.
54,59,60
Elastic tissue abnormalities may also contribute to 
the  frequently  encountered  leg  ulcerations  in  TI 
patients and may explain the observed development 
of  transfusion-induced  arterial  hypertension  in 
sickle cell anaemia and -thalassemia patients
61,62. 
On  the  other  hand,  the  thalassemia-related 
hypercoagulability, sometimes in combination with 
the elastic tissue defects, has been held responsible 
for  a  high  frequency  of  thromboembolic 
complications.  Thromboembolic  events  were
encountered  in  two  large  cohorts  of  thalassemia 
patients,  including  both  TM  and  TI,  with  a 
frequency of 4.3% και 5.2%, respectively.
63,64 It is 
noteworthy that the prevalence of such events was 
higher  in  splenectomised  patients  than  in  non-
splenectomised ones. In particular, thromboembolic 
complications  were  even  more  frequent  in 
transfusion-independent  splenectomised  TI  (29%), 
compared  to  regularly  transfused  TM  (2%),  a 
finding  that emphasizes  the  role  of  transfusion 
therapy  in  the  inhibition  of  hypercoagulability  in 
thalassemia patients.
65 Such events comprised deep 
vein  thrombosis  (40%),  portal  vein  thrombosis 
(19%),  pulmonary  thromboembolism  (12%), 
cerebral  thrombosis  (9%)  as  well  as  recurrent 
arterial  occlusion  and  others  (20%).  A  recently 
published  multinational  cohort  comprising  8,860 
thalassaemia  patients  from  the  Mediterranean 
region and Iran showed that thromboembolic events 
were 4.38 times more frequent in TI than in TM, 
and  were  particularly  prevalent  in  splenectomised 
patients  and  patients  with  profound  anaemia 
(haemoglobin  level  <90  g/l).
66 Ischemic  strokes 
have  also  been  described  in  combination  with 
cardiac  valvular  lesions  – a  consequence  of  the 
elastic tissue defect and/or atrial fibrillation
54 on a 
background  of  hypercoagulability.  At  the  same 
time,  thrombosis  may  be  a  silent,  subclinical 
process,  as  autopsy  findings  of  thrombi  in  the 
microvasculature  of  lungs  and  brain  have  been 
described in the absence of clinical manifestations 
or other known risk factors.
67
Right  heart  involvement:  Right  sided  heart 
involvement in Th may result from both pulmonary 
hypertension  (PHT)  and  severe  iron  overload. In 
well transfused and chelated TM, PHT is rare. It is 
however,  presenting  with  increasing  frequency  in 
TM,  particularly  those  who  are  poorly  transfused 
and chelated, even at younger ages.
68 Those, who 
are  adequately  transfused  but  who  are  poorly 
chelated,  may  present  with  dominant  right  sided 
heart  involvement
69 with  hepatic  distension  and 
pain  with minimal  dyspnoea, without evidence of 
PHT. PHT represents a prominent complication in 
TI. Almost 60% of cases in a large cohort of 110 
adult  TI  patients  had  developed  PHT.
42 More 
specifically, peak systolic tricuspid gradient values 
>30mmHg,  indicative  of  pulmonary  hypertension, 
were present in 59.1% of TI that was age related, 
while values >50 mmHg were present in 7.3% of 
cases.  Additional  reports  confirmed  the  above 
finding,
70-72 while a recent study that compared TI 
with TM showed that PHT is a typical feature of 
non-transfused  TI  and  not  a  simple  age-related 
effect due to their prolonged survival.
43 PHT seems 
to be the leading cause of congestive heart failure in 
TI, due to the subsequent right heart insufficiency 
usually  with  maintenance  of  LV  function.  The 
combination  of  high  output  state  and  increased 
pulmonary  vascular  resistance  has  been  held 
responsible for  the  development  of  PHT.
42,43 It is 
more pronounced in TI than in well transfused TM. 
The increased pulmonary vascular resistance in -
thalassemia  is  multifactorial.  The  fact  that  most 
subtypes of  chronic  haemolytic  anemia  may 
develop pulmonary hypertension suggests that there 
is a pathogenic link between the two conditions.
71
The role of chronic haemolysis in the development 
of PHT through the induction of nitric oxide and 
arginine  deficiency,  which  promotes 
vasoconstriction,  has  been  recently  stressed.
50 At Medit J Hemat Infect Dis 2009; 1.
the same time, as stated above, haemolysis has also 
been associated with the coexistent diffuse elastic 
tissue  defect.  Degenerative  elastic  tissue  lesions 
have been encountered in  pulmonary autopsies in 
patients  with  haemoglobinopathies, such  as sickle 
cell  disease.
73 Moreover,  endothelial  dysfunction 
promotes  hypercoagulability and  in  situ  thrombus 
formation within the pulmonary vascular bed. In -
thalassemia,  in  particular,  the  oxidative  stress 
resulting from chronic haemolysis is enhanced by 
the  presence  of  iron  overload  and  free-radical 
formation and the expected effect seem to be more 
pronounced. In addition, iron overload is associated 
with interstitial pulmonary fibrosis and may affect 
pulmonary  vascular  resistance.
72
Hypercoagulability, as discussed above, is a well-
described  co-morbid  state  in  -thalassemia, 
especially in non-transfused TI patients. Extensive 
thromboembolic  lesions  have  been  found  in  the 
pulmonary  arterioles  of  splenectomised 
thalassaemics in post-mortem autopsies, leading to 
the reduction of the total pulmonary vascular bed
67. 
Lung  infections,  chest  deformities  intrathoracic 
extramedullary haemopoietic masses and transient 
LV dysfunction may also contribute to pulmonary 
vascular resistance.
42 All the mechanisms for PHT 
development  can  be  inhibited  by  adequate 
transfusion and chelation therapy and explain why 
that finding is a rare phenomenon in TM.
Left  ventricular  involvement:  The  main 
mechanism of left ventricular involvement in Th is 
iron overload and secondarily the increased cardiac 
output. The reduction in LVEF is a major element 
in TM for cardiomyopathy and the worst prognostic 
feature  with  respect  to  patient  survival.  In  well 
transfused TM (pre transfusion Hb > 95g/l) the iron 
overload  predominates  and  in  TI  the  increased 
cardiac  output  is  prominent.  Furthermore,  the 
resulting  elevation  of  systemic  impedance  that  is 
presented to left ventricle leads to a less favourable 
interaction  between  left  ventricular  ejection  and 
systemic arterial compliance, which contributes to 
left ventricular impairment.
74,75 These changes are 
aggravated  by  the  advancing  age.  Besides 
peripheral  vascular  disorders,  the  coexistence  of 
coronary  artery  involvement,  infections  related  to 
iron load, endocrine abnormalities, arrhythmias and 
valvular  lesions,  render  left  ventricular function 
more susceptible to decompensation. Th are more 
likely to present with overt cardiac dysfunction in 
situations  of  stress,  such  as  excessive  physical 
activity  or  other  conditions  requiring  increase 
cardiac work load as fever or significant anaemia. 
In situations of increased stress, particularly in TI, 
LV  cardiac  decompensation  may  present  with 
sudden worsening of preexisting PHT due to further 
increase in pulmonary vascular resistance.
Chelation  treatment  for  prevention  and 
treatment of iron induced heart disease.
Chelation  therapy:  Comprehensive  treatment  of 
both TM and TI is beyond the scope of this review.
The approach to prevention and reversal of cardiac 
disease  is  principally  based  on  TM.  However  for 
both TM and TI (once the decision to transfuse is 
made),  it  is  important  to  minimize  the  cardiac 
output with adequate levels of pre-transfusion Hb (> 
95g/l in general and higher if there is evidence of 
PHT or marginal cardiac function) and to remove 
the iron. The monitoring to determine the degree of 
cardiac  iron  overload  is  by  Cardiac  Magnetic 
Resonance  (CMR)  T2*  assessment.  Chelation 
treatment today should be guided by MRI findings, 
if the technique is available. We are in a transient 
phase  of  knowledge with  the  availability  of  MRI 
and new chelating agents. Important questions with 
respect to best management to avoid iron induced 
cardiac  disease remain  to  be  elucidated. Optimal 
management  may  be  clarified  from  results  of 
different  trials  and  current  ongoing  follow  up 
studies  from  many  subgroups  of  patients  using 
different regimes.In the presence of excess cardiac 
and  or  hepatic  iron,  treatment  strategies  include 
increase  of  the  dose  and/or  frequency  of 
desferrioxamine,  switch  to  oral  chelators 
(deferiprone or deferasirox) or to the combination 
of deferiprone with desferrioxamine, provided there 
are  no  contraindications  to  their  use.
76,77
Combination  of  the  two  iron  chelators 
(desferrioxamine  and  deferiprone)  seems  to 
maximize  the  efficacy  producing  additive  and 
synergistic  effects  in  iron  excretion.
78,79  It  seems 
that  each  of  those  two  agents  chelates  iron  from 
different pools and there is at least an additive effect 
when combined treatment is administered.
80
Available evidence now suggests that combined 
therapy  should  be  the  treatment  of  choice  for 
patients with established cardiac failure. Continuous 
desferrioxamine infusions alone, have been shown 
to improve cardiac function and salvage patients
81
and  is  the  treatment  of  choice  if  combination 
therapy is contraindicated. We have reported two 
cases with severe CCF who reversed with intensive 
combination  therapy
82,83 and  we  have  at  least  8 
more patients  with  similar  outcome. Two  other 
studies  show  similar  responses.
84,85 In  a  recent 
study  with  combined  treatment,  apart  from 
significant  reduction  in  ferritin,  cardiac  and  liver 
iron  and  improvement  in  cardiac  function,  the 
absolute endothelial function was also improved
77. Medit J Hemat Infect Dis 2009; 1.
Furthermore,  improvement  with  glucose  tolerance 
with  the  use  of  combination  therapy  has  been 
reported
86,87  as  well  as  anecdotal  reports  of 
improvement in other endocrine functions. 
With  respect  to  hepatic  iron  removal,  the 
efficacy of the two oral chelators is at least equal to 
the standard doses of desferrioxamine
20,88,89. Recent 
and  ongoing  studies  have  demonstrated  that 
deferiprone,  a  small molecule  that  permeates  all 
tissues, is more efficient in removing cardiac iron 
and  improving  cardiac  function  than 
desferrioxamine.
20,90,91 Some  preliminary  clinical 
and  laboratory  observations  with  deferasirox  are 
encouraging  with  respect  to  removal  of cardiac 
iron.
92,93 As  yet,  there  are  no  studies  with 
combinations of deferasirox and desferrioxamine so 
this therapeutic regime cannot be recommended at 
this stage. According to the current knowledge and 
based  on  the  CMR  findings, the  suggested 
chelation regimes are as follows:
Acceptable Cardiac Iron: For patients with T2* > 
20  ms.,  the  therapeutic  strategy  should  be 
continuation  of monotherapy  with  either 
desferrioxamine  or  either  of  the  available  oral 
chelators  (deferiprone  and  desferasirox) with 
regular  follow-up.  For  the  patient’s  convenience, 
desferrioxamine administration may be converted to 
either of the two oral chelators. If there has been 
iron  overload  in  the  past  that  was  attributed  to 
desferrioxamine therapy and that was subsequently 
cleared  with  intensification  of  chelation  therapy, 
then  monotherapy  with  desferrioxamine  is  not 
recommended. 
Mild  to  Moderate  Cardiac  Iron  Loading:  T2* 
values between 10-20ms are considered to reflect a 
mild  to  moderately  iron  loaded  myocardium. 
Bearing in mind that the patients may be at risk of 
developing cardiac  problems  under  stress  such  as 
infections,  clearing  myocardial  tissue  from  iron 
seems to be a rational target. Therefore, combined 
treatment for these patients should not be a priori 
excluded.  Patients have  presented  with  LV 
dysfunction at levels of T2* of 15 msec, without 
any precipitating factors.
19,77 Therefore, if T2* is ≤ 
15  msec,  combination  chelation  therapy  is 
recommended.
76 However,  questions  still  exist, 
regarding  the  frequency  and  the  amount of 
desferrioxamine  administration  that  is  appropriate 
in a combined regimen. A dose of 35-40mg/kg/day 
three-four times weekly combined with deferiprone 
at a dose of 75mg/kg/day seems to be reasonable.  
In patients with T2* 15-20 ms, monotherapy with 
deferiprone  and  deferasirox  are  available 
options.
20,88 However,  in  this  circumstance  close 
monitoring is necessary. Patients treated up to the 
time  of  the  MRI  with  desferrioxamine  in  this 
category  and  who  availed  themselves  of  that 
treatment satisfactorily, in general should not be on 
monotherapy  with  that  compound, as 
desferrioxamine  was  inadequate  at  preventing  the 
iron  accumulation  in  the  heart  and  may  indicate 
some type of resistance to its efficacy within that 
patient. If  however,  the  patient’s  adherence  to 
treatment  with  it  was  poor,  then  it  may  be 
appropriate in higher doses and frequency, provided 
the patient can be convinced to use it.
Heavy  Cardiac  Iron  Load:Patients  with  T2* 
<10msec  are  considered  to  have  severe  iron 
overload  and this  category  includes  most patients 
with  reduced left ventricular (LV) function. Even 
those patients with normal ejection fraction in this 
category are considered to have a significant risk of 
developing cardiac dysfunction. Thus all patients in 
this category have a strong indication for combined 
chelation  treatment. The  doses  of  the  two 
medications should be similar to those described for 
patients  with  CCF  (see  below)  but  with  the 
desferrioxamine  being  given  as  a  subcutaneous 
infusion.  If  deferiprone  is  contraindicated,  then 
intensive  intravenous  continuous  desferrioxamine 
infusions are the treatment of choice.
Heart  Failure: For  patients  with  heart  failure 
desferrioxamine should be administrated at a dose 
of 60-80mg/kg/day intravenously and deferiprone at 
a dose of 75-100mg/kg/day in three divided doses. 
If deferiprone is contraindicated, the patient should 
be  managed  with  continuous  desferrioxamine 
infusions, which usually require the placement of an 
indwelling  catheter
94. It  seems  however,  that  the 
rate of removal of iron with such therapy is much 
slower  than  with  combination  therapy.
77 Caution 
should  be  taken  with  the  24h  desferrioxamine 
infusion  to  avoid  fluid  overload  especially  when 
intravenous antibiotics and anti arrhythmic  agents 
are also indicated.
Treatment  Modifications:  Any  treatment 
modification  should  be  followed  by  close 
monitoring.  Should  any  serious  adverse  effect 
present as a consequence of the administration of a 
particular chelator, appropriate guidelines as to its 
continued use should be followed. If treatment has 
ultimately modified the MRI patient’s classification 
then,  it  may  be  adjusted  as  discussed  above 
according to the changes in MRI values. In all of 
the above, hepatic iron and endocrine status should 
also  be  considered  and  modification  to  the 
recommended regimes should be made in order to 
achieve normal hepatic iron levels in the long term.
Guidelines if MRI is not available: In situations in 
which MRI is not available, then all the patients’ Medit J Hemat Infect Dis 2009; 1.
traditional  parameters  need  to  be  analysed, 
(ferritins, liver iron concentrations) as well as ECG 
and echocardiogram. These may serve as a guide to 
treatment. Furthermore,  according  to  knowledge 
from  MRI  studies,  all  patients  with  reductions  in 
LVEF  have  excessive  cardiac  iron  load. Any 
echocardiographic  evidence  of  reduce  cardiac 
function should be considered as being associated 
with  excessive  cardiac  iron  load  and  should  be 
managed accordingly. In countries where follow up 
of patients has become available and who had been 
treated with desferrioxamine, up to 65% of patients 
have cardiac iron load. In Sardinia, 13% had severe 
cardiac  iron  overload.
29 In  our  study  48%  of 
patients  have  T2*  <  15  ms
19.  In  countries  were 
patients’  compliance  to  treatment  is  inadequate, 
there was poor availability of chelation and/or the 
follow up was not well organized, the percentage of 
cardiac iron loaded patients is likely to be higher.
Therefore, for patients who have never had optimal 
care, it is very likely the patients will have cardiac 
iron load and intensive combination chelation is the 
treatment  of  choice. In  patients  who  have  been 
poorly  chelated,  the  risk  of  chelation  toxicity  is 
minimal  and  would  only  be  likely  to  occur  after 
prolonged therapy, however, it is  important to  be 
vigilant for such complications. If compliance with 
desferrioxamine has been an issue, as evidenced by 
high ferritin or hepatic iron, then either of the two 
available oral chelators is appropriate therapy. MRI 
is more necessary for those patients, who have had 
good  chelation  therapy  with  desferrioxamine  but 
who are at risk of chelation inadequacy with respect 
to the heart and for those who have had   treatment 
modification in order to follow the efficacy of the 
changed chelation regime. 
Conclusions  on  Heart  Disease:  This  formerly 
catastrophic genetic defect has been revolutionized 
with the availability of adequate chelation therapy 
and  more  recently  with  other  important  advances 
particularly  MRI  .  Iron  related  heart  failure  is 
reversible in TM provided appropriate interventions 
are made in a timely manner. It should no longer be 
considered a terminal event and intensive attention 
to  the  parameters  mentioned  above  can  result  in 
complete reversal with markedly improved quality 
of life.It remains important, practically, to  aim to 
maintain low LIC’s and ferritin levels in Th (both 
TM and  TI),  particularly  as  the  latter  are  easily 
accessible  and  assessable. Similarly, 
echocardiography should remain a routine tool as it 
does have some predictive value and can also be 
used to monitor patients in whom intensification of 
chelation therapy has been instituted.CMR can be 
particularly helpful in identifying all TM patients at 
risk  of  developing  heart  disease  by  assessing  the 
cardiac iron load. Chelation therapy can be tailored 
to  remove  the  excess  heart  iron.  Attention  to 
patient’s  continuous  compliance  with  adequate 
chelation is mandatory.The definite ability to know 
and reduce cardiac iron as well as improvement in 
cardiac function that can be achieved by appropriate 
chelation,  should  certainly  lead  to  even  further 
significant  reduction  in  cardiac  mortality  and 
morbidity.
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